Compare Gigacloud Technology Inc (GCT) vs Gilead Sciences, Inc. (GILD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gigacloud Technology Inc vs Gilead Sciences, Inc. — how do they compare? Gigacloud Technology Inc trades at $57.25 (market cap $2.02B), while Gilead Sciences, Inc. trades at $150.89 (market cap $182.40B). The key difference: Gilead Sciences, Inc. is far larger — about 90.3× Gigacloud Technology Inc's market cap, and Gilead Sciences, Inc. pays a 2.23% dividend while Gigacloud Technology Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Gigacloud Technology Inc for 21 Days and Gilead Sciences, Inc. for 111 Days on average.
| GCT | GILD | |
|---|---|---|
Market Cap | $2.02B | $182.40B |
Volume | 1,020,985 | 4,469,821 |
Sector | Technology | Health |
52-Week High | $56.42 | $155.80 |
52-Week Low | $25.46 | $116.74 |
Typical Hold Time | 21 Days | 111 Days |
Enterprise Value | $2.14B | $205.46B |
Dividend Yield | — | 2.23% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GCT trades at $57.02, up 1.89% today, showing strong momentum with consistent earnings beats in recent quarters. The stock exhibits bullish technical signals with moving averages supporting upward trends, while fundamentals reveal solid profitability with 10.65% net margins and robust ROE of 32.34%. Recent news highlights institutional interest and European expansion driving growth.
Outlook remains positive with analyst consensus favoring buys (66.7%) and revenue projected to grow to $1.5B in 2026. Key risks include insider selling and competitive pressures in consumer discretionary sector. The stock trades at reasonable valuation multiples (P/E 13.44) with upside potential to consensus target of $32.50.
Gilead Sciences (GILD) trades at $150.72, up 2.64% with a bullish technical signal and strong analyst support (65.5% buy ratings). Recent quarterly earnings have consistently beaten expectations, though Q2 2026 showed a significant loss. The company maintains robust operating cash flow ($10.02B in 2025) and is expanding HIV prevention access through new partnerships, positioning for growth despite a negative net income margin of -10.64%.
Outlook is cautiously optimistic with a consensus price target of $151.57, slightly above current levels. Key opportunities include pipeline advances in oncology and HIV treatments, while risks involve profitability volatility, high debt levels, and competitive pressures. The stock's valuation metrics suggest moderate pricing relative to earnings but elevated on sales and book value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Gigacloud Technology Inc
Gigacloud Technology operates a global B2B e-commerce marketplace for large-parcel goods. It provides a comprehensive solution for furniture manufacturers and retailers with integrated logistics and fulfillment.
Read more on GCT →About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →
